CCIA
RNAM

Campbell & Co Investment Adviser’s Avidity Biosciences RNAM Stock Holding History

Campbell & Co Investment Adviser’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-9,913
Closed -$455K – 1316
2024
Q3 		$455K Sell
9,913
-5,463
-36% -$237K 0.03% 752
2024
Q2 		$628K Sell
15,376
-55,319
-78% -$1.59M 0.05% 559
2024
Q1 		$1.8M Buy
+70,695
New +$1.11M 0.16% 171

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Campbell & Co Investment Adviser's RNAM Position: Q4 2024 in Review

Campbell & Co Investment Adviser sold out of Avidity Biosciences (RNAM) in Q4 2024, closing a stake of 9,913 shares — an estimated $455K sold.

Campbell & Co Investment Adviser first reported a position in RNAM in Q1 2024 and held it in 3 quarters. The position peaked at $1.8M in Q1 2024. 236 funds tracked by Wall St. Rank hold RNAM as of Q4 2024.

  • Campbell & Co Investment Adviser reported no remaining Avidity Biosciences position as of Q4 2024 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 9,913 Avidity Biosciences shares in Q4 2024, an estimated $455K.
  • Campbell & Co Investment Adviser first reported a position in Avidity Biosciences in Q1 2024 and held it in 3 quarters.
  • Campbell & Co Investment Adviser's Avidity Biosciences position peaked at $1.8M in Q1 2024.
  • 236 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2024.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2024, filed 10 Feb 2025.